The administration of drugs to the central nervous system (CNS) is primarily controlled by
the blood-brain barrier (BBB), a structure that prevents the passage of foreign compounds …

The management of the central nervous system (CNS) disorders is challenging, due to the
need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the …

In last two decades, the lipid nanocarriers have been extensively investigated for their drug
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …

Nose-to-brain drug delivery has been of great interest for the treatment of many central
nervous system (CNS) diseases and psychiatric disorders over past decades. Several …

Parkinson's disease (PD) is the second leading neurodegenerative disease globally,
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …

Neuropsychiatric diseases are one of the main causes of disability, affecting millions of
people. Various drugs are used for its treatment, although no effective therapy has been …

The research work was intended to formulate teriflunomide (TFM) loaded nano lipid-based
(TNLC) carbopol-gellan gum in situ gel (TNLCGHG) and to investigate its therapeutic …

Rivastigmine is a drug commonly used in the management of Alzheimer's disease that
shows bioavailability problems. To overcome this, the use of nanosystems, such as …

Abstract Quality-by-design (QbD) approach has been applied to optimize lipid-based
nanosystems formulations, including solid lipid nanoparticles (SLN), nanostructured lipid …

Scientific research has focused its attention on finding an alternative route to systemic oral
and parenteral administration, to overcome their usual drawbacks, such as hepatic first-pass …